Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
2cureX ABFRA:2QE +0.38%37 Buyback Yield % is 0.00 as of Jul. 21, 2026. GuruFocus rates FRA:2QE with a GF Score™ of 37/100. The stock has 3 warning signs investors should review. Among 740 Biotechnology companies, 2cureX AB ranks worse than 135135% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for 2cureX AB's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2QE vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, 2cureX AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
2cureX AB Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 2cureX AB's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where 2cureX AB's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2cureX AB (FRA:2QE) has a Buyback Yield % of 0.00 as of Jul. 21, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on 2cureX AB and its competitors. According to the industry distribution chart, 2cureX AB ranks #999999 out of 740 companies in the Biotechnology industry.
Is 2cureX AB's Buyback Yield % too high?
2cureX AB's current Buyback Yield % is 0.00. Based on the distribution chart, 2cureX AB ranks #999999 out of 740 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, 2cureX AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does 2cureX AB's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 2cureX AB ranks #999999 out of 740 companies for Buyback Yield %. This places 2cureX AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on 2cureX AB and its competitors. 2cureX AB's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 2cureX AB stock overvalued right now?
2cureX AB (FRA:2QE) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. 2cureX AB's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For 2cureX AB (FRA:2QE), the current Buyback Yield % is 0.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.
37GF Score
Get the complete analysis for FRA:2QE
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2QE has been successfully added to your 
